ISSN: 2574-187X
Authors: Patidar A, Saini S and Vinchurkar K*
The inherited condition known as androgenetic alopecia (AGA) causes hair to become thinner. In both men and women, it is the most prevalent kind of alopecia. Numerous therapy techniques have been researched in recent years, but only topical minoxidil and finasteride have received US Food and Drug Administration approval. A minimally invasive procedure called microneedling (MN) promotes the creation of growth factors, neovascularization, and collagen. In spite of MN hasn't been the subject of many studies in alopecia, but it's still a promising treatment therapeutic option, but there isn't a standardised strategy treating MN hair loss not yet proposed. The evidence available now is insufficient to provide a direct comparison with Despite showing potential to improve hair quality, thickness, and density in comparison to alternative treatments of hair, especially when used as a medication or in conjunction with other therapies delivery mechanism. The purpose of this article is to review the literature that is currently accessible on use of MN either by itself or in combination with other treatments to treat androgenetic alopecia.
Keywords: Dermarol; Collagen Induction Treatment; Androgenetic Alopecia; USFDA; Microneedling
